Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis
07 sept. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the screening for the RESULT Phase 3 clinical study has surpassed the halfway...
Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
06 sept. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference
05 sept. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
28 août 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
Trend toward preservation of renal function (eGFR) in blisibimod treated patientsLack of disease progression, as measured by proteinuria in blisibimod treated patients HAYWARD, Calif., Aug. 28, 2017...
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
14 août 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due...
Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
09 août 2017 16h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug...
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
09 août 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
RESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study...
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network
10 juil. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due...
Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura
06 juil. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
Study is being conducted in the US, Europe, and IsraelTop line data expected end of 2017 or early 2018 HAYWARD, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Anthera (Nasdaq:ANTH) today announced that...
Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
15 mai 2017 16h02 HE
|
Anthera Pharmaceuticals, Inc.
Four-week non-inferiority, Coefficient of Fat Absorption (CFA) primary endpoint comparing Sollpura to Pancreaze in patients with exocrine pancreatic insufficiency due to cystic fibrosisStudy design...